- Home
- LVLU vs NERV Comparison
LVLU vs NERV Comparison
Compare LVLU & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- NERV
- Stock Information
- Founded
- LVLU 1996
- NERV 2007
- Country
- LVLU United States
- NERV United States
- Employees
- LVLU N/A
- NERV N/A
- Industry
- LVLU Catalog/Specialty Distribution
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- NERV Health Care
- Exchange
- LVLU Nasdaq
- NERV Nasdaq
- Market Cap
- LVLU 12.4M
- NERV 14.6M
- IPO Year
- LVLU 2021
- NERV 2014
- Fundamental
- Price
- LVLU $4.97
- NERV $4.32
- Analyst Decision
- LVLU Hold
- NERV Hold
- Analyst Count
- LVLU 1
- NERV 1
- Target Price
- LVLU $15.00
- NERV $4.00
- AVG Volume (30 Days)
- LVLU 242.1K
- NERV 8.7M
- Earning Date
- LVLU 11-12-2025
- NERV 11-05-2025
- Dividend Yield
- LVLU N/A
- NERV N/A
- EPS Growth
- LVLU N/A
- NERV N/A
- EPS
- LVLU N/A
- NERV N/A
- Revenue
- LVLU $285,413,000.00
- NERV N/A
- Revenue This Year
- LVLU N/A
- NERV N/A
- Revenue Next Year
- LVLU $2.53
- NERV N/A
- P/E Ratio
- LVLU N/A
- NERV N/A
- Revenue Growth
- LVLU N/A
- NERV N/A
- 52 Week Low
- LVLU $2.98
- NERV $1.15
- 52 Week High
- LVLU $22.25
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- LVLU 50.32
- NERV 59.26
- Support Level
- LVLU $4.38
- NERV $3.75
- Resistance Level
- LVLU $6.16
- NERV $4.20
- Average True Range (ATR)
- LVLU 0.39
- NERV 0.39
- MACD
- LVLU 0.04
- NERV -0.05
- Stochastic Oscillator
- LVLU 27.53
- NERV 63.85
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.